Report

Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10

See allHide authors and affiliations

Science  25 Aug 2000:
Vol. 289, Issue 5483, pp. 1352-1355
DOI: 10.1126/science.289.5483.1352

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to secrete the cytokine. Intragastric administration of IL-10–secretingLactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10−/− mice. This approach may lead to better methods for cost-effective and long-term management of IBD in humans.

  • * To whom correspondence should be addressed. E-mail: lothar.steidler{at}dmb.rug.ac.be

  • These authors contributed equally to this work.

View Full Text